Biotech, small-cap, micro-cap, long only

Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets

Cellceutix Corp (OTCQB:CTIX) is based in Beverly, Massachusetts and is a clinical stage biotech company. Their product pipeline was doubled with the PolyMedix asset acquisition and now includes three drugs actively in development.

The biotechnology space has been hopping with acquisitions in 2013 as big pharma looks to refuel dwindling pipelines with new therapeutics and stave off shrinking revenue as rivals introduce generic versions of blockbuster drugs. Amgen (AMGN) shares have been on the rise since the company on August 26 said that it will spend $10.4 billion, or $125 per share, to acquire Onyx Pharmaceuticals (ONXX). The purchase is the second largest in Amgen's history, with only the $17-billion acquisition of Immunex in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details